Mattson R H, Cramer J A, Collins J F
Neurology Service, Department of Veterans Affairs Medical Center, West Haven, CT 06516, USA.
Neurology. 1996 Jul;47(1):68-76. doi: 10.1212/wnl.47.1.68.
Two prospective observations of adults with symptomatic, localization-related (partial) epilepsy included 1,102 patients in VA multicenter studies (VA-118 and VA-264). Analyses assessed the likelihood of remaining seizure free for 12 and 24 months after initiating adequate antiepileptic drug therapy.
Patients were grouped as having only secondarily generalized tonic-clonic seizures (GTC), only complex partial seizures (CPS), or both types (MIXED) at entry. The cumulative proportion of patients remaining seizure free with standard antiepileptic drug therapy was determined by actuarial life table methods.
At 12 months, 70% and 61% of GTC patients (VA-118 and VA-264, respectively) had no further GTC; 53% and 50% of MIXED, predominantly GTC patients had no further GTC, 21% and 28% of CPS patients had no further CPS and 98% and 91% were seizure free for GTC; 32% and 35% of MIXED, predominantly CPS patients had no further CPS, and 62% and 51% of patients with MIXED seizure types remained seizure free for CPS for 12 months after enrollment.
The overall prognosis for control of seizures of any type for 12 months was best for those who had only GTC at entry (55% and 48%), worst for those who had only CPS at entry (23% and 26%), and intermediate for those with MIXED seizures at entry (32% and 25%) (all p < 0.0001). Prognosis can be based on the predominant seizure type in patients with multiple types.
两项针对有症状的、局灶性(部分性)癫痫成人患者的前瞻性观察研究纳入了1102例患者,这些研究来自退伍军人事务部(VA)的多中心研究(VA - 118和VA - 264)。分析评估了在开始充分的抗癫痫药物治疗后12个月和24个月无癫痫发作的可能性。
患者在入组时被分为仅患有继发性全面强直阵挛发作(GTC)、仅患有复杂部分性发作(CPS)或两种发作类型都有(混合型)。采用精算生命表法确定接受标准抗癫痫药物治疗后无癫痫发作的患者累积比例。
在12个月时,GTC患者(分别来自VA - 118和VA - 264)中70%和61%没有进一步的GTC发作;以GTC为主的混合型患者中53%和50%没有进一步的GTC发作,CPS患者中21%和28%没有进一步的CPS发作,98%和91%的患者GTC发作停止;以CPS为主的混合型患者中32%和35%没有进一步的CPS发作,入组后12个月,混合型发作类型的患者中62%和51%的患者CPS发作停止。
对于入组时仅患有GTC的患者,控制任何类型癫痫发作12个月的总体预后最佳(55%和48%),入组时仅患有CPS的患者预后最差(23%和26%),入组时患有混合型发作的患者预后居中(32%和25%)(所有p < 0.0001)。对于多种发作类型的患者,预后可基于主要发作类型判断。